Video narration
If there is no IV comparison, comparing two formulations gives relative bioavailability instead. These are comparisons of exposure, not just labels on packages. Bioequivalence asks a narrower question: do test and reference formulations produce sufficiently similar exposure? Researchers commonly compare test-to-reference ratios for AUC and Cmax, using a prespecified confidence interval. In many settings, the 90 percent interval must fall within 80 to 125 percent; requirements can differ by drug or regulator. That range is a decision rule, not a demand for identical curves. So return to the graph. Matching dose alone cannot answer the opening question. Bioequivalence means the dose-adjusted AUC and peak-level comparisons meet the applicable limits-not that the curves, or every patient's concentrations, are identical.